[artículo] 
inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 2 (Abril) . - pp. 135-144

Título :	Efficacy and safety of agomelatine in the treatment of major depressive disorder : A multicenter, randomized, double blind, placebo controlled trial
Tipo de documento:	texto impreso
Autores:	John M. Zajecka, Autor ; Alan F. Schatzberg, Autor ; Stephen M. Stahl, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 135-144
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Etiquetas:	Agomelatina, Antidepresivos, Trastorno depresivo mayor, Sueño
Resumen:	In this 8-week double-blind multicenter trial, we evaluated the efficacy and safety of 2 fixed doses of agomelatine in patients with moderate to severe major depressive disorder. Primary efficacy variable was the change in 17-item Hamilton Depression Rating Scale (HAM-D17) total score from baseline to week 8/end of treatment.
Link:	./index.php?lvl=notice_display&id=29458

[artículo] Efficacy and safety of agomelatine in the treatment of major depressive disorder : A multicenter, randomized, double blind, placebo controlled trial [texto impreso] / John M. Zajecka, Autor ; Alan F. Schatzberg, Autor ; Stephen M. Stahl, Autor . - 2022 . - pp. 135-144.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 2 (Abril) . - pp. 135-144

Etiquetas:	Agomelatina, Antidepresivos, Trastorno depresivo mayor, Sueño
Resumen:	In this 8-week double-blind multicenter trial, we evaluated the efficacy and safety of 2 fixed doses of agomelatine in patients with moderate to severe major depressive disorder. Primary efficacy variable was the change in 17-item Hamilton Depression Rating Scale (HAM-D17) total score from baseline to week 8/end of treatment.
Link:	./index.php?lvl=notice_display&id=29458